- Opinion
- [Reporter's view] Strategies for Trial & error/the evolution
- by An, Kyung-Jin Aug 25, 2020 06:14am
- In August, there was a lot of good news in the pharmaceutical and bio industry. Hanmi and Yuhan, leading domestic pharmaceutical companies, announced the news of the signing of a global technology transfer contract for the new drug pipeline, revealing the potential of R&D. The license agreements of domestic companies are developing. Earlie
- Policy
- Started to develop the generic for Norspan Patch
- by Lee, Tak-Sun Aug 25, 2020 06:11am
- The development of generic drug for 'Nospan Patch', a narcotic pain reliever that has been growing recently, has begun. Samyang Biopharm has received approval for the bioequivalence test from the Ministry of Food and Drug Safety. Northpan patch has no patents on the PMS and patent list, but there is no same active ingredient so far. On
- Policy
- Followup of drug price agreement, possible by electronically
- by Kim, Jung-Ju Aug 25, 2020 06:11am
- When the NHIS concludes a drug price negotiation with a pharmaceutical company, a legal basis will be prepared for notifying the company in writing or electronically of the details of the subsequent proceedings. The purpose of this is to increase administrative convenience so that insurance benefits work more efficiently. The MOHW announc
- Policy
- Forsteo reduced pricing effective from Aug. 25
- by Kim, Jung-Ju Aug 25, 2020 06:10am
- As the South Korean court ruled against Lilly Korea’s litigation claiming unfair pricing reduction on its osteoporosis treatment Forsteo (teriparatide), the government would execute the order as planned initially. The insured pricing reduction would be enforced on Aug. 25, but it could be suspended again if the company decides to take
- Policy
- Democratic Party submits 5 bills to curb spiking COVID-19
- by Lee, Jeong-Hwan Aug 24, 2020 06:19am
- The ruling party readies for a full-on quarantine measures by introducing a series of bills to curb COVID-19 resurging in South Korea centering a far-right church in Seoul metropolitan area. On Aug. 20 and 21, the Democratic Party submitted five bills to the National Assembly (NA) to strengthen the existing regulations to contain the rap
- Company
- Celltrion begins to develop oral Remsima following SC type
- by Kim, Jin-Gu Aug 24, 2020 06:19am
- Celltrion starts developing oral 'Remsima'. Celltrion announced on the 20th that it has signed a joint research agreement with British biotechnology company Intract Pharma. Remicade, Remsima's original drug, is a drug administered by intravenous injection.. Celltrion has already developed and commercialized Remsima SC, the first in the wor
- Policy
- Tagrisso and Eliquis pricing lowered 4% through PVA
- by Kim, Jung-Ju Aug 24, 2020 06:18am
- The insured pricing of AstroZeneca Korea’s Tagrisso tablet (osimertinib mesylate) and Bristol-Myers Squibb’s (BMS) Eliquis tablet (apixaban) would be lowered by approximately 4 percent from next month due to pricing-volume agreement (PVA). According to the pharmaceutical industry sources, South Korea’s Ministry of Health and Welfare (MOHW
- Company
- United promotes phase III tx for COVID-19 in the Philippines
- by Aug 24, 2020 06:18am
- Korea United Pharmaceutical (CEO Kang Deok-young) is starting to develop a cure for COVID-19. It is Drug Repositioning of the company's Incrementally Modified Drug 'UI030'. United said on the 19th, "UI030 has confirmed the antiviral effect of up to 30 times compared to Ciclesonide in cell experiments." According to the company, UI030 is
- Company
- Patent dispute for Promac, eventually to Supreme Court
- by Kim, Jin-Gu Aug 24, 2020 06:18am
- The patent dispute over the anti-ulcer drug, Promac (Polaprezinc) was finally concluded in the Supreme Court. According to the pharmaceutical industry on the 19th, SK Chemical, which holds a formulation patent for Promac, recently filed an appeal to the Supreme Court against Hana Pharm and Korea Prime. Earlier, on the 17th of last month
- Welcoming preemptive measures to protect generic exclusivity
- by Lee, Tak-Sun Aug 21, 2020 06:27am
- Most of the pharmaceutical industry is welcoming the plan to improve the generic for exclusivity items contained in the amendment to the Pharmaceutical Affairs Act on the 20th. It is a "preemptive measure" for the method of restricting the patentee's deletion of patents from the patent list after the generic has received generic exclusivity.
